Inception- 2018

Location- Mumbai

Domain- Genomics

Founder- Dr Anirvan Chatterjee (Chief Executive Officer), Gaurav Srivastava (Chief Operating Officer), Prof Kiran Kondabagil (Chief Scientific Mentor)

Total team strength- 20 (R&D-5; Operations- 6; Sales & Outreach-5; Support-4)

Total funds raised – Rs 1.55 crore

Investors- Nidhi Prayas, Birac Seed Support, DST Cawach, BIRAC Big Grant, DST Intel-Plugin Investment

Revenue generated since inception- Rs 30 lakh
 
Key Highlights-

• In 2018-19- initiated the development of first genomic analysis product for tuberculosis
• In 2019-20- Awarded Nidhi Prayas grant for R&D in tuberculosis drug sensitivity testing
• In 2020-21- Developed hardware technology (α box) to allow any molecular diagnostic lab to run the HaystackAnalytics genomic analysis directly on their bench
• Launched Tuberculosis genomic analysis for mass patient use
• Developed genomic analysis for COVID-19
• Initiated project on RNA-seq assessment of multiple myeloma
• Tuberculosis genomic analysis test onboarded by 2 major national diagnostic chains and several other regional diagnostic labs and some leading hospitals
• Developed a single genomic test for major pathogens and antimicrobial resistance
• Genomic analysis platform for COVID-19 analysis developed and work initiated with Municipal Corporation of Greater Mumbai

Founder Speaks-

"Being one of the very few genomic companies on the GE Healthcare’s India Edison Accelerator platform, we believe there is a tremendous opportunity to learn from each other's capabilities while we work together to shape this evolving market.  Genomics has now been accepted as part of healthcare diagnostics, treatment monitoring, drug discovery, etc. In India, acceptance of a technology will rely on scalability, ease-of-use and the ability to be a complete 1-test solution. By enabling existing labs to perform and analyze genomics, there is tremendous opportunity for growth."

- Dr Anirvan Chatterjee, Chief Executive Officer, HaystackAnalytics, Mumbai